Harrow (HROW) Q1 2026 Earnings Transcript

Harrow reported Q1 revenue of $44.2 million and adjusted EBITDA of negative $12.7 million, but management said the quarter was intentionally the low point of the year and reaffirmed 2026 revenue guidance of $350 million to $365 million. VEVYE posted $20.9 million of revenue, with an $8 million gross-to-net adjustment viewed as isolated to Q1; demand remained strong with NRx up 25% sequentially, TRx up 11%, and branded share reaching about 14%. IHEEZO, TRIESENCE, and Access+ all showed improving demand trends, while BYOOVIZ, IOPIDINE’s July 1 J-code, and commercial force expansion are expected to drive a stronger second half.

Analysis

The core signal here is not the headline miss, but that the company is transitioning from a demand-constrained story to an execution-constrained one. The reset in VEVYE economics appears to be a one-off pricing model correction rather than a demand problem, which matters because the stock should re-rate on the durability of prescription growth once the market accepts that Q1 was an artificially depressed base. The bigger second-order effect is commercial leverage: with the sales force now fully deployed, every incremental script in the back half should carry materially better operating leverage than in Q1, so the market is likely underestimating gross margin and EBITDA inflection in Q3/Q4.

The most interesting competitive dynamic is around payer and channel behavior, not product efficacy. By tightening business rules on covered lives and leaning harder into cash-pay for select buckets, management is effectively segmenting patients by economics; that can improve ASP but may also accelerate competitor poaching if access friction rises in the wrong plan mix. The CVS commentary is the tell: if one payer cohort was unusually dilutive, then the next few quarters should show a sharp mix benefit, but only if utilization stays intact after the reimbursement cleanup.

On IHEEZO, the near-term revenue profile is intentionally noisy because the company is trading away a legacy channel for a bigger in-office opportunity. That creates a temporary valuation gap: reported growth may lag underlying unit demand through Q2, then re-accelerate once packaging and pricing changes land in Q3. The market may be missing that the new J-code on IOPIDINE is not just incremental revenue; it is a customer-relationship wedge that can increase wallet share inside the same physician offices and reduce selling cost per incremental dollar across the franchise.

Key Decisions for Investors

• Go long HROW on any post-earnings weakness over the next 1-3 weeks; this is a setup for a Q3/Q4 re-rating as the market digests the VEVYE ASP reset and the sales force fully ramps. Risk/reward is favorable if the stock is pricing Q1 as a run-rate quarter.
• Pair trade: long HROW / short a basket of slower-growing ophthalmology or specialty pharma names with weaker commercial leverage for the next 2-3 quarters. The thesis is that HROW should show the sharpest sequential inflection once pricing normalizes and channel inventory clears.
• Buy HROW call spreads expiring after Q3 results to express upside from BYOOVIZ, IOPIDINE, and improved VEVYE economics. Best strike structure is one that targets a moderate rerate rather than a blowout launch scenario, since execution is the more likely catalyst than a single-step TAM expansion.
• If holding CVS exposure, reduce or hedge modestly: HROW’s comments imply some specialty drug economics are being optimized against payer mix, which can pressure PBM / managed-care economics at the margin if similar patterns appear elsewhere. Near-term impact is small, but it is a reminder that reimbursement normalization can create localized margin leakage for intermediaries.
• Wait for confirmation rather than chasing IHEEZO-driven strength immediately after July catalysts. The cleaner entry is after the market sees whether the Q3 revenue conversion actually catches up to the unit demand inflection.